Targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs) have revolutionized the management of rheumatologic conditions, but they carry risks for unique and severe adverse effects. Match each clinical vignette describing a therapy-related complication with the specific medication class most likely responsible.
- A 52-year-old man with refractory rheumatoid arthritis develops new-onset exertional dyspnea, orthopnea, and pitting lower extremity edema three months after starting a biologic agent; an echocardiogram reveals a newly reduced left ventricular ejection fraction of 35%.Tumor necrosis factor-alpha (TNF-alpha) inhibitors
- A 61-year-old woman with severe rheumatoid arthritis on a biologic agent develops progressive cognitive decline, hemiparesis, and ataxia over several weeks; brain MRI demonstrates non-enhancing, asymmetric white matter lesions without mass effect.Anti-CD20 monoclonal antibodies
- A 58-year-old man of Mediterranean descent with refractory tophaceous gout receives a new intravenous urate-lowering therapy and presents three days later with acute jaundice, dark urine, and a peripheral smear showing bite cells and Heinz bodies.Recombinant uricase
- A 64-year-old woman with rheumatoid arthritis develops a severe, intensely painful vesicular eruption in a dermatomal distribution across her right thorax shortly after adding a new oral targeted synthetic DMARD to her regimen.Janus kinase (JAK) inhibitors
Answer
The correct mappings are:
1. The patient with new-onset heart failure matches with TNF-alpha inhibitors.
2. The patient with Progressive Multifocal Leukoencephalopathy (PML) matches with Anti-CD20 monoclonal antibodies.
3. The patient with G6PD-associated hemolytic anemia matches with Recombinant uricase.
4. The patient with Herpes zoster reactivation matches with Janus kinase (JAK) inhibitors.
1. The patient with new-onset heart failure matches with TNF-alpha inhibitors.
2. The patient with Progressive Multifocal Leukoencephalopathy (PML) matches with Anti-CD20 monoclonal antibodies.
3. The patient with G6PD-associated hemolytic anemia matches with Recombinant uricase.
4. The patient with Herpes zoster reactivation matches with Janus kinase (JAK) inhibitors.
Each advanced rheumatologic medication class operates via distinct pathophysiologic mechanisms that lead to highly specific toxicities. TNF-alpha inhibitors depress myocardial function. Anti-CD20 agents deplete B-cells allowing opportunistic JC virus reactivation. Recombinant uricase generates oxidative stress, unmasking G6PD deficiency. JAK inhibitors impair antiviral signaling, predisposing specifically to VZV reactivation.
Step-by-Step Solution
Key Concept
Severe and unique adverse effect profiles of targeted DMARDs and biologic therapies in rheumatology.
Estimated Time:2m 0s